Stocks Beats on Views- Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Biocept, Inc. (NASDAQ:BIOC)

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) [Trend Analysis] tries to capture market sentiments, shares build up 1.32% to $115.17. Zimmer Biomet Holdings, Inc. (ZBH) reported that preliminary financial results for the fourth quarter and full year ended December 31, 2016. Based on preliminary unaudited financial information, the Company expects fourth quarter net sales to be approximately $2.013 billion, an increase of 4.1% over the prior year period.

On an adjusted, constant currency basis, income surged by 4.4% over the prior year period, with the recently acquired LDR Holding Corporation contributing approximately 230 basis points. Excluding the contribution from the LDR transaction and adjusting for one less billing day in the quarter, the Company estimates that revenues surged 3.5% over the fourth quarter of 2015. Previously, the Company had estimated fourth quarter income growth to be in a range of 1.0% to 2.0% on a similar basis.

Preliminary full year net sales are projected to be $7.684 billion, an increase of 28.1% over the prior year. On a constant currency, adjusted pro forma basis, the Company expects that full year income surged by 3.4% over the prior year, with the recently acquired LDR Holding Corporation contributing approximately 110 basis points. Therefore, full year revenues surged by 2.3% on a constant currency, adjusted pro forma basis, excluding the contribution from the LDR transaction. Previously, the Company had estimated full year income growth to be in a range of 1.65% to 1.90% on a similar basis.

When calculating EPS estimates for the current year from sell-side analysts, the Price to current year EPS stands at -81.50%. Investors looking further ahead will note that the Price to next year’s EPS is 9.33%. (What Market Forces Produce Volatility in NYSE:ZBH Share? Find Free Report Here)

As for as concerns shares volumes, in share of capital Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has 200.28 million outstanding shares among them 199.57 million shares have been floated in market exchange. ZBH institutional ownership remained 88.40% while insider ownership included 15.00%. The firm attains analyst recommendation of 2.00 with week’s performance of 10.01%

Biocept, Inc. (NASDAQ:BIOC) [Trend Analysis] shows fluctuation in active trade, on Wednesday shares jumped up 62.98% to $2.95. Biocept, Inc. (BIOC) reported that it has secured an in-network provider contract with Blue Cross Blue Shield of Texas (BCBSTX), the largest provider of health benefits in that state. “Determining the molecular status of a tumor can help physicians individualize treatment for their patients and our highly sensitive Target Selector platform can provide this important information from a simple blood sample,” said Biocept’s Senior Vice President and Senior Medical Director Veena Singh, MD. “Our liquid biopsy testing is changing the way physicians evaluate tumor status and monitor both response and resistance to treatment.”

“It is gratifying that health plans are seeing the value of our liquid biopsy approach for profiling and monitoring important cancer biomarkers,” said Michael Nall, President and Chief Executive Officer of Biocept.

“Partnering with health insurers is a major focus of our business strategy, as it may increase physician access to this non-invasive technology for their patients and provide timely adjudication of claims for patients. Securing this in-network contract is an important milestone for Biocept, as Texas is one of our largest markets and BCBSTX is the largest provider in that state. With this contract, the number of patients with in-network access to our tests has grown to approximately 185 million, with some members having access via multiple plans.”

The 52-week high of the share price is 56.91% and 52-week low of the share price is 502.04%. Current stock price is in the upbeat territory taking into account of 20 days moving average with 225.31% and continued bullish run for 50 days moving average with 238.85%.

Moving toward technical analysis, the current ratio, or the liquidity ratio of a company was calculated 0.30. To take look on ration of tradable shares being shorted in market, float short ration was 6.61%, as compared to sentiment indicator; Short Ratio was 1.54. Taking notice in average true range, it was 0.12.

For latest Market Updates Subscribes Here


Steve Hart

Steve Hart is a longtime business journalist who has covered everything from municipal bonds to management, major banks and MBA programs. Prior to becoming a writer at Seneca Globe News, Steve Hart was a securities analyst and a budget and fiscal analyst. Steve can be reached at

Leave a Reply

Your email address will not be published. Required fields are marked *